Ottawa researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects.
While Dr. Bell and his colleagues have been investigating replicating viruses for the treatment of solid cancers for many years, with very promising results, this is the first major success they have had treating blood cancer (leukemia). It is also the first success they have had using a non-replicating virus-derived particle as opposed to a replicating virus.
“Our research indicated that a replicating virus might not be the safest or most effective approach for treating leukemia, so we decided to investigate whether we could make virus-derived particles that no longer replicate but still kill cancer,” said Dr. Conrad, a hematologist conducting research in the Blood and Marrow Transplant Program at The Ottawa Hospital, and currently completing his PhD at OHRI and uOttawa in the Department of Cellular and Molecular Medicine. “We were delighted to see that this novel therapy was very safe at high doses, and worked extremely well in our laboratory leukemia models. We hope to test this in patients in the near future.”
The researchers used a specific method and dose of UV light to transform regular replicating viruses into unique particles that could no longer replicate and spread, but could still enter cancer cells efficiently, kill them and stimulate a strong immune response against the cancer. These particles were able to kill multiple forms of leukemia in the laboratory, including samples taken from local patients who had failed all other therapies. Normal blood cells were not affected. This novel treatment was also successful in mouse models of leukemia. In fact, 80 per cent of the mice that received the therapy had markedly prolonged survival and 60 per cent were eventually cured, while all of the untreated mice died of their leukemia within 20 days.
“Leukemia is a devastating disease that can be very difficult to treat, and new therapies are urgently needed,” said Dr. Conrad. “While we’re still at the early stages of this research, I think this therapy holds a lot of promise because it appears to have a potent, long-lasting effect on leukemia without the debilitating side effects of many cancer therapies used in the clinic right now.
The Latest Bing News on:
- Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruseson February 26, 2021 at 3:02 am
The development of H7N9 vaccines has mainly focused on LPAI virus-derived candidate vaccine viruses (CVVs). However, HPAI and LPAI viruses are antigenically distinct; ferret antisera raised by ...
- HIV - 1 Nef: At the Crossroadson February 25, 2021 at 4:00 pm
 HIV-2 is a zoonotic virus derived from sooty mangabeys.  It has reduced pathogenicity relative to HIV-1 overall, but progression to AIDS can occur.  Consistent with reduced ...
- MAIT cell activation augments adenovirus vector vaccine immunogenicityon February 3, 2021 at 6:57 pm
S1E). (A to C) Human PBMCs (n = 9 donors; four experiments) were stimulated with Ad5-GFP or ChAdOx1-GFP [multiplicity of infection (MOI) = 0 to 10 4 vp (viral particles)]. MAIT cell CD69 (A), granzyme ...
- Integumen Plc Share Chaton September 8, 2020 at 9:50 pm
The risk of the virus derived from rivers for cooling towers is slim to nil for a number of reasons. The first thing to consider is this. Many studies have shown that the highest risk of virus ...
- Bridging efficient viral infectionon April 22, 2019 at 12:33 pm
These experiments revealed the presence of viral particles on the surface of the membrane bridge, coincident with the virus-derived structures revealed by fluorescent microscopy. Clearly ...
The Latest Google Headlines on:
The Latest Bing News on:
Non-replicating virus-derived particle
- Feed has no items.